Philips Integrates Cloud-based AI and 3D Mapping into its Mobile C-arm System Series – Zenition

To enhance workflow efficiency and improve endovascular treatment outcomes

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced physicians will now have access to advanced new 3D image guidance capabilities through its Image-Guided Therapy Mobile C-arm System – Zenition, delivering enhanced clinical accuracy and efficiency, and aiming to improve the outcomes for patients undergoing endovascular treatment. The company has signed a strategic partnership agreement with Cydar, a UK-based provider of cloud-based procedure maps software to plan and guide surgery in real time.

As patient numbers rise and procedures become more complex and time-consuming, patient-specific real-time procedure planning and guidance, optimization of equipment utilization, and usability have become ever more important. To help overcome these challenges, Philips Image-Guided Therapy Mobile C-arm System – Zenition – brings together innovations in image capture and processing, ease-of-use, and versatility, many of which were pioneered on Philips’ highly successful image guided therapy platform Azurion. Like Azurion, the Zenition mobile C-arm system allows hospitals to maximize operating room performance, enhance their clinical capabilities, and provide staff with a seamless user experience. The integration of Cydar EV Maps software into the Zenition platform now adds extended procedure planning and real-time 3D guidance capabilities.

Cloud-based AI and computer vision

Cydar EV Maps assists in the planning, real-time guidance, and post procedure review of endovascular surgery. It brings cloud-based AI and computer vision to mobile surgery, enabling reductions in radiation exposure, fluoroscopy time, and procedure time together with improved ease of use [1,2]. It enables surgeons to create a detailed patient-specific 3D map of the target vasculature to help plan surgery, and then uses these maps to augment intraoperative live image-guidance, updating the maps in real time to account for deformations during surgery, such as guidewires and instruments deforming the patient’s blood vessels. Cydar EV also facilitates post procedure outcome analysis. The combined result of this integration of procedure planning, guidance and review is that surgeons can work more accurately and efficiently – enabling an approximate 50% reduction in radiation exposure [1], a significant reduction in fluoroscopy time and a reduction of procedure times by more than 20% [2], while helping achieve better outcomes for patients.

“With Philips’ integrated portfolio, using validated AI and cloud technologies, we can facilitate collaborative care to optimize surgical pathways,” said Karim Boussebaa, General Manager Image Guided Therapy Systems at Philips. “Philips has a strong global network of mobile surgery systems and recognizes that Cydar’s EV Maps solution can play a key role in further improving our integrated offering for endovascular procedures.”

“By partnering with Philips to bring our Cydar EV Maps solution to Philips’ user-friendly Zenition platform of mobile C-arms, we are a step closer to achieving our mission to ensure every image-guided minimally-invasive surgical procedure goes exactly as planned,” said Paul Mussenden, CEO of Cydar. “The benefits of this combined solution, with integrated and enhanced procedure planning and visualization, include shorter and more predictable procedure times, reduced X-ray exposure to patients and staff, and fewer injections of iodine dye – the leading cause of in-hospital kidney failure.”

Cydar EV Maps is currently in use across the EU, UK and US. It is certified Software-as-a-Medical Device with EU CE mark and U.S. FDA 510(k) clearances.


References

[1] Southerland K, Nag U, Turner M, Gilmore B, McCann R, Long C, Cox M, Shortell C. IF09. Image-Based Three-Dimensional Fusion Computed Tomography Decreases Radiation Exposure, Fluoroscopy Time, and Procedure Time During Endovascular Aortic Aneurysm Repair. J Vasc Surg. 2018;67: e61-e61
[2] Shortell C., Veithsymposium New York, 2017

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

LumiGuide, powered by Fiber Optic RealShape (FORS) technology, enables doctors to navigate through blood vessels using light, instead of X- ray. “[It’s] one of the most exciting changes that we’ve seen with imaging certainly throughout my career,” said Andres Schanzer, Vascular Surgeon, at UMass Memorial Medical Center, Worcester, MA, USA.
Carestream Health notes twenty-seven of the patents were awarded by the U.S. Patent and Trademark Office; an additional 43 patents were received in European and Asian countries.
According to an Insightec study, patients experienced significant reductions in upper limb tremor, tremor-related disability, and quality of life. The most common intraprocedural adverse events included dizziness, headache, nausea, and vomiting, which all resolved. Post-procedural adverse events included paraesthesia and gait disturbance, which were often transient or resolved within 12 months.
Chris Landon, Business Leader Image Guided Therapy Devices at Philips: “IVUS is a technology that has demonstrated an ability to both support safer procedures for patients and procedural staff alike including reductions in radiation exposure. As the global leader in IVUS solutions, we are grateful for the rigorous multidisciplinary approach to developing expert consensus on the value of IVUS and we look forward to working with all stakeholders to standardize the use of IVUS and reduce the barriers preventing utilization.”
"We are delighted to see our 3D solution CE-marked and available on the European market," says Ulrik Harrysson, CEO at SyntheticMR AB. "SyMRI 3D represents the next generation of quantitative MRI, offering unprecedented resolution and accuracy in brain imaging, revolutionizing the landscape of medical diagnostics."

By using this website you agree to accept Medical Device News Magazine Privacy Policy